0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
STOP COVID
Lenze (DB RCT)
93%
0.07 [0.01-0.52]
1,200mg
progression
0/80
6/72
Improvement, RR [CI]
Dose (4d)
Treatment
Control
Seftel (QR)
84%
0.16 [0.01-3.29]
500mg
death/ICU
0/77
2/48
STOP COVID 2
Reiersen (DB RCT)
-201%
3.01 [0.12-73.6]
800mg
oxygen
1/272
0/275
Seo (SB RCT)
0%
1.00 [0.15-6.57]
800mg
progression
2/26
2/26
COVID-OUT
Bramante (DB RCT)
-11%
1.11 [0.33-3.61]
400mg
death/hosp.
6/329
5/324
OT1
Pineda
94%
0.06 [0.01-0.52]
800mg
death
1/594
4/63
Farahani (DB RCT)
51%
0.49 [0.24-1.02]
400mg
PASC
42 (n)
43 (n)
LONG COVID
TOGETHER
Reis (DB RCT)
-200%
3.00 [0.12-73.5]
800mg
death
1/738
0/738
CT2
EFFaCo
Siripongbo.. (RCT)
-2%
1.02 [0.26-4.00]
400mg
oxygen
4/162
4/165
Tsiakalos
67%
0.33 [0.01-7.84]
800mg
ICU
0/53
1/50
Fluvoxa
Siripongboonsitti
59%
0.41 [0.02-9.98]
400mg
death
0/234
1/518
Wannigama (RCT)
98%
0.02 [0.00-0.34]
500mg
ventilation
0/162
32/336
Tau2 = 0.31, I2 = 26.0%, p = 0.042
Early treatment
49%
0.51 [0.26-0.98]
15/2,769
57/2,658
49% lower risk
TOGETHER
Reis (DB RCT)
30%
0.70 [0.37-1.26]
800mg
death
17/741
25/756
Improvement, RR [CI]
Dose (4d)
Treatment
Control
Calusic (ICU)
42%
0.58 [0.36-0.94]
1,200mg
death
30/51
39/51
ICU patients
Kirenga
68%
0.32 [0.19-0.53]
800mg
death
29/94
126/222
ACTIV-6
Stewart (DB RCT)
31%
0.69 [0.27-1.21]
700mg
progression
14/589
21/586
Tau2 = 0.11, I2 = 71.2%, p = 0.0013
Late treatment
48%
0.52 [0.35-0.77]
90/1,475
211/1,615
48% lower risk
Oskotsky (PSM)
-58%
1.58 [0.42-5.93]
n/a
death
2/11
19/165
Improvement, RR [CI]
Dose (1m)
Treatment
Control
Fritz
19%
0.81 [0.26-2.22]
n/a
hosp./ER
4/17
1,896/20,457
Diaz (PSM)
28%
0.72 [0.63-0.81]
n/a
cases
4,558 (n)
4,558 (n)
Trkulja (PSM)
27%
0.73 [0.35-1.55]
n/a
death
Visos-Varela
-103%
2.03 [0.24-17.4]
n/a
death
case control
Tau2 = 0.00, I2 = 0.0%, p < 0.0001
Prophylaxis
27%
0.73 [0.65-0.82]
6/4,586
1,915/25,180
27% lower risk
All studies
39%
0.61 [0.47-0.78]
111/8,830
2,183/29,453
39% lower risk
21 fluvoxamine COVID-19 studies
c19early.org
March 2024
Tau2 = 0.09, I2 = 50.3%, p = 0.00014
Effect extraction pre-specified(most serious outcome, see appendix)
1 OT: comparison with other treatment2 CT: study uses combined treatment
Favors fluvoxamine
Favors control